Immunohistochemical expression of COX2 and iNOS in bladder cancer and its association with urinary schistosomiasis among Sudanese patients

Infectious Agents and Cancer

Hussain Gadelkarim Ahmed⁴  Amel Omer Bakhiet¹  Ahmed Abdel Badie Mohamed³  Hassan Elsiddig Hassan² 

[1] Department of Pathology, Faculty of Vet. Medicine, Sudan University of Science and Technology, Khartoum, Sudan;Department of Histopathology and Cytology, Faculty of Medical Laboratory Science Sudan University of Science and Technology, Khartoum, Sudan;Department of Pathology, Faculty of Medicine, Elribat National University, Khartoum, Sudan;Department of Histopathology and Cytology, Faculty of Medical Laboratory Science, University of Khartoum, Khartoum, Sudan

关键词: Schistosomiasis;    Bladder cancer;    iNOS;    COX2;   

Others  :  803151
DOI  :  10.1186/1750-9378-8-9

 received in 2012-06-03, accepted in 2013-02-11,  发布年份 2013

【 摘 要 】

Aims

The purpose of this study was to determine if any relationship exists between expression of COX2 and iNOS markers and urinary schistosomiasis in bladder cancers.

Methodology

Immunohistochemical expression of COX2 and iNOS was assessed in formalin fixed paraffin wax processed tissues obtained from 155 patients with bladder cancers (87 SCC and 68 TCC) and 39 patients with benign bladder cystitis.

Results

The overall immune-expressions of COX2 and iNOS were 71.6% and 57.2% respectively, of the 194 bladder lesions. A significant Positive association between COX2 or iNOS expression with bladder lesions (SCC, TCC and cystitis) was found (p.value = 0.000). COX2 and iNOS were co-expressed among 73(83.9%) of SCC, 15(22.1%) of TCC and 11(28.2%) of the cystitis group. The relationship between COX2 and iNOS immunostaining and Schistosomal ova positivity was statistically determined by P values 0.0565 and 0.1223 for Cox2 and iNOS, respectively.

Conclusion

There are high rates of positive expression of COX2 and iNOS among Sudanese patients with Schistosomal-related bladder lesions. There might be strong association between high rates of bladder cancers and urinary Schistosomiasis in the Sudan since, the great majority of lesions were positive for COX2.

【 授权许可】

   
2013 Hassan et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ferlay J, Bray F, Pisan P, Parkin DM, Globocan: Cancer incidence, mortality and prevalence worldwide (2002), version 1.0. IARC Cancer Base No. 5. Lyoo: IARC press; 2004.
• [2]Heyns CF, Van der Merwe A: Bladder cancer in Africa. Can J Urol 2008, 15:3899-3908.
• [3]Gouda I, Mokhtar N, Bilal D, El-Bolkainy T, El-Bolkainy NM: Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Canc Inst 2007, 19:158-162.
• [4]Felix AS, Soliman AS, Khaled H, Zaghloul MS, Banerjee M, El-Baradie M: The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control 2008, 19:421-429.
• [5]Yu XC: Cyclooxygenase −2 Inhibitors in Cancer treatment and prevention: a recent development. Anti Cancer Drug 2002, 13:127-137.
• [6]Shirahama T: Molecular oncology, Marker, Clinical Correlates: Cyclooxygenase −2 Expression is up – regulated in transitional cell carcinoma and its Preneoplastic Lesions in the human urinary bladder. Clin Cancer Res 2000, 6:2424-2430.
• [7]TsuJii M, Kawano S, Dubios RW: Cyclooxygenase −2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997, 94:3336-3340.
• [8]Li GO, Yang T, Li L, Yan J, Zeng Y, Yu J: Cyclooxygenase-2 Parallels invasive depth and increased MVD in transitional cell carcinoma. Cell surf Biointer 2004, 37:9-15.
• [9]Wadhwa P, Goswami AK, Joshi K, Sharma SK: Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol Nephrol 2005, 37:47-53.
• [10]Palacios M, Knowles RG, Palmer RM, Moncada S: Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophy Res Commun 1989, 165:802-809.
• [11]Nathan C, Xie QW: Regulation of biosynthesis of nitric oxide. J Biol Chem 1994, 269:13725-13728.
• [12]Bhagat K, Vallance P: Nitric oxide 9 years on. J R Soc Med 1996, 89:667-673.
• [13]Lin Z, Chen S, Ye C, Zhu S: Nitric oxide synthase expression in human bladder cancer and its relation to angiogenesis. Urol Res 2003, 31:232-235.
• [14]Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA, Weiss RM: Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol 1999, 161:630-634.
• [15]El Gehani K, Al-Kikhia L, Emaetig F, Syrjänen K, Al-Fituri O, Elzagheid A: Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder. Libyan J Med 2012, 7:10.
• [16]Johansson SL, Cohen SM: Epidemiology and etiology of bladder cancer. Semin Surg Onco 1997, 13:291-298.
• [17]Malik MO, Veress B, Daoud EH: Pattern of bladder cancer in the Sudan and its relation to schistosomiasis: a study of 255 vesical carcinomas. J Trop Med Hyg 1975, 78:219-223.
• [18]Abdulamir AS, Hafidh R, Kadhim HS, Abubakar F: Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. Clin Cancer Res 2009, 28:27. BioMed Central Full Text
• [19]Harris L, Fritsche H, Mennel R: American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
• [20]Shirahama T, Sakakura C: Overexpression of Cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clinical Cancer Res 2001, 7:558-561.
• [21]Moussa M, Omran Z, Nosseir M, Lotfy A, Swellam T: Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma. APMIS 2009, 117:45-52.
• [22]Hammam OA, Ahmed AA, Mamdouh SR, Ahmed MAH: Possible Role of Cyclooxygenase-2 in Schistosomal and Non-Schistosomal-Associated Bladder Cancer. Medscape J Med 2008, 10:234-237.
• [23]Youssef R, Kapur P, Kabbani W, Shariat SF, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y: Bilharzial versus non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. BJU Int 2011, 108(1):31-37.
• [24]Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-142.
• [25]Bredt DS, Snyder SH: Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 1994, 63:175-195.
• [26]Chhatwal VJS, Ngoi SS, Chan STF: Aberrant expression of nitric oxide synthase in human polyps, neoplastic colonic mucosa and surrounding peri tumoral normal mucosa. Carcinogenesis 1994, 15:2081-2085.
• [27]Jenkins DC, Charles IG, Baylis SA: Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br J Cancer 1994, 70:847-849.
• [28]Salim EI, Morimura K, Menesi A, El-Lity M, Fukushima S, Wanibuchi H: Elevated oxidative stress and DNA damage and repair levels in urinary bladder carcinomas associated with schistosomiasis. Int J Cancer 2008, 123(3):601-608.